ifosfamide has been researched along with Neuroblastoma in 41 studies
Neuroblastoma: A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred seventy-three eligible patients more than 1 year of age with disseminated neuroblastoma received two courses of one of the following: ifosfamide (IFOS) 2 g/m2/d for 4 days intravenously (IV) plus mesna; carboplatin (CARB) 560 mg/m2 i." | 9.07 | Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. ( Berkow, RL; Buchanan, GR; Cantor, AB; Castleberry, RP; Green, AA; Hayes, FA; Joshi, V; Leventhal, B; Mahoney, DH; Smith, EI, 1994) |
| "Three patients with stage 4 neuroblastoma were treated with a schedule comprising alternating modules of myelosuppressive (ifosfamide, etoposide, doxorubicin) and less myelosuppressive (vincristine, cisplatin) drugs given every 10 days regardless of the neutrophil count." | 9.07 | Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin. ( Craft, AW; Lowis, SP; Pearson, AD; Reid, MM, 1993) |
| "Twenty-five patients with progressive or recurrent neuroblastoma were treated with single-agent ifosfamide." | 9.06 | Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group. ( de Kraker, J; Hartmann, O; Ninane, J; Pritchard, J, 1987) |
| "The authors report a retrospective analysis of high-dose ifosfamide, carboplatin, and etoposide (HD-ICE) for patients with refractory or relapsed neuroblastoma (NB)." | 8.89 | Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. ( Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS, 2013) |
| "Patients older than 1 year with either metastatic or localised stage 2-3 MYCN-amplified neuroblastoma received 2 courses of high-dose topotecan (HD-TPT) 6mg/m(2) and high-dose cyclophosphamide (HD-CPM) 140 mg/kg, followed by 2 courses of ifosfamide, carboplatin and etoposide (ICE) every 28 days." | 7.77 | Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma. ( Castellano, A; De Ioris, MA; De Pasquale, MD; De Vito, R; Donfrancesco, A; Garganese, MC; Ilari, I; Inserra, A; Jenkner, A; Locatelli, F; Natali, G; Ravà, L, 2011) |
| "Recurrent and refractory neuroblastoma responds well to chemotherapy regimen of ifosphamide plus carboplatin." | 7.73 | [Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006) |
| "A prospective study of the effectiveness of ifosfamide as a single agent in the management of previously untreated patients with Evans stage IV neuroblastoma was undertaken." | 7.67 | Ifosfamide in previously untreated disseminated neuroblastoma. Results of Study 3A of the European Neuroblastoma Study Group. ( Bowman, A; De Kraker, J; Kellie, SJ; Lilleyman, JS; Pritchard, J, 1988) |
| "The esthesioneuroblastoma is a rare neuroendocrine tumor that derives from the olfactory cells." | 5.36 | Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine. ( Biamonte, R; Ceniti, S; Conforti, S; De Simone, R; Filice, A; Liguori, V; Manfredi, C; Mastroianni, C; Palazzo, S; Patitucci, G; Rovito, A; Turano, S; Viscomi, C, 2010) |
| "Childhood neuroblastoma is a neural crest-derived tumor that presents most commonly during this period of life." | 5.28 | Combination chemotherapy with ifosfamide and etoposide is effective in the treatment of central nervous system metastasis of childhood neuroblastoma. ( Watts, RG, 1992) |
| "Twenty-nine patients diagnosed with recurrent neuroblastoma or PNET were treated with a combination chemotherapy regimen of cisplatin, 160 mg/m(2)/96 hours; doxorubicin, 40 mg/m(2)/96 hours; and escalated doses of etoposide and ifosfamide." | 5.09 | A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma. ( Fernandez, MC; Gerbing, RR; Krailo, MD; Matthay, KK, 2000) |
| "One hundred seventy-three eligible patients more than 1 year of age with disseminated neuroblastoma received two courses of one of the following: ifosfamide (IFOS) 2 g/m2/d for 4 days intravenously (IV) plus mesna; carboplatin (CARB) 560 mg/m2 i." | 5.07 | Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. ( Berkow, RL; Buchanan, GR; Cantor, AB; Castleberry, RP; Green, AA; Hayes, FA; Joshi, V; Leventhal, B; Mahoney, DH; Smith, EI, 1994) |
| "Three patients with stage 4 neuroblastoma were treated with a schedule comprising alternating modules of myelosuppressive (ifosfamide, etoposide, doxorubicin) and less myelosuppressive (vincristine, cisplatin) drugs given every 10 days regardless of the neutrophil count." | 5.07 | Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin. ( Craft, AW; Lowis, SP; Pearson, AD; Reid, MM, 1993) |
| "Twenty-five patients with progressive or recurrent neuroblastoma were treated with single-agent ifosfamide." | 5.06 | Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group. ( de Kraker, J; Hartmann, O; Ninane, J; Pritchard, J, 1987) |
| "The authors report a retrospective analysis of high-dose ifosfamide, carboplatin, and etoposide (HD-ICE) for patients with refractory or relapsed neuroblastoma (NB)." | 4.89 | Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. ( Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS, 2013) |
| "Phase II studies conducted in Europe and the USA on pediatric solid tumors have shown that ifosfamide, as a single agent, is an active drug against a variety of neoplasms - rhabdomyosarcoma (RMS), some non-RMS soft tissue sarcomas, Wilms' tumor, bone sarcomas and neuroblastoma." | 4.82 | Ifosfamide in pediatric solid tumors. ( Bisogno, G; Carli, M; Passone, E; Perilongo, G, 2003) |
| "Patients older than 1 year with either metastatic or localised stage 2-3 MYCN-amplified neuroblastoma received 2 courses of high-dose topotecan (HD-TPT) 6mg/m(2) and high-dose cyclophosphamide (HD-CPM) 140 mg/kg, followed by 2 courses of ifosfamide, carboplatin and etoposide (ICE) every 28 days." | 3.77 | Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma. ( Castellano, A; De Ioris, MA; De Pasquale, MD; De Vito, R; Donfrancesco, A; Garganese, MC; Ilari, I; Inserra, A; Jenkner, A; Locatelli, F; Natali, G; Ravà, L, 2011) |
| "Recurrent and refractory neuroblastoma responds well to chemotherapy regimen of ifosphamide plus carboplatin." | 3.73 | [Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006) |
| "Neuroblastomas, nephroblastomas, malignant mesenchymal tumors, including rhabdomyosarcomas, Ewing's sarcomas, osteosarcomas, brain tumors, and non-Hodgkin's lymphomas respond to ifosfamide monotherapy." | 3.69 | Ifosfamide in the treatment of pediatric malignancies. ( Behrendt, H; de Kraker, J; Michiels, E; van den Berg, H; Voûte, PA, 1996) |
| "We studied two children with recurrent cancer, who during treatment with ifosfamide developed severe encephalopathy characterized by coma of several days duration." | 3.67 | Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors. ( Barak, LS; Estrada, J; Gieron, MA, 1988) |
| "A prospective study of the effectiveness of ifosfamide as a single agent in the management of previously untreated patients with Evans stage IV neuroblastoma was undertaken." | 3.67 | Ifosfamide in previously untreated disseminated neuroblastoma. Results of Study 3A of the European Neuroblastoma Study Group. ( Bowman, A; De Kraker, J; Kellie, SJ; Lilleyman, JS; Pritchard, J, 1988) |
| "Neuroblastoma is the most common extracranial and deadly solid tumor in children." | 2.76 | Did salvage ICE chemotherapy improve the outcome in primary resistant/relapsing stage III/IV neuroblastoma? ( Abdel Rahman, H; El Debawy, E; Ezzat, S; Mostafa, NE; Moussa, EA; Rayan, Ael R; Yones, A; Zekri, WZ, 2011) |
| "(4) Characteristics of second neoplasms: Among the seven children with second neoplasms, five children had leukemia, 3 patients with rhabdomyosarcoma were combined with radiotherapy." | 1.72 | A report on second neo-plasms in seven children with solid tumors. ( Hu, H; Huang, D; Li, F; Li, J; Li, R; Liu, Z; Zhang, W, 2022) |
| "Adult neuroblastoma is an extremely infrequent neoplasm, usually occurring in the adrenal medulla or in the paraspinal sympathetic ganglia, as its childhood counterpart." | 1.51 | Extra-Adrenal Adult Neuroblastoma With Aberrant Germ Cell Marker Expression: Maturation After Chemotherapy as an Important Clue to a Challenging Diagnosis. ( Berbegall, AP; Blanquer-Maceíras, MT; Ferrández, A; Machado, I; Martinez-Ciarpaglini, C; Navarro, S; Nieto, G; Noguera, R; Yoshida, A, 2019) |
| "Methylene blue and thiamine have been occasionally successful as treatment." | 1.43 | The Use of Continuous Veno-Venous Hemodiafiltration in the Management of Ifosfamide-induced Encephalopathy: A Case Report. ( HaDuong, JH; Yeo, KK, 2016) |
| "Patients with infratentorial brain metastases of highly malignant pediatric non-epithelial tumors are in a severe clinical state, but still can have longer and useful lives with aggressive multimodal treatments combined with radical surgical resection." | 1.37 | Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports. ( Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M, 2011) |
| "The esthesioneuroblastoma is a rare neuroendocrine tumor that derives from the olfactory cells." | 1.36 | Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine. ( Biamonte, R; Ceniti, S; Conforti, S; De Simone, R; Filice, A; Liguori, V; Manfredi, C; Mastroianni, C; Palazzo, S; Patitucci, G; Rovito, A; Turano, S; Viscomi, C, 2010) |
| "Neuroblastoma is the most common extracranial solid malignancy in children but rarely described in adults, being 10% of all cases diagnosed after the first decade of life." | 1.36 | Neuroblastoma in an adult: case report. ( Ferreti Bonan, PR; Martelli-Júnior, H; Miranda Soares, PB; Pereira DE Souza, W; Quirino Filho, S, 2010) |
| "Childhood neuroblastoma is a neural crest-derived tumor that presents most commonly during this period of life." | 1.28 | Combination chemotherapy with ifosfamide and etoposide is effective in the treatment of central nervous system metastasis of childhood neuroblastoma. ( Watts, RG, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (12.20) | 18.7374 |
| 1990's | 12 (29.27) | 18.2507 |
| 2000's | 12 (29.27) | 29.6817 |
| 2010's | 11 (26.83) | 24.3611 |
| 2020's | 1 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, H | 1 |
| Zhang, W | 1 |
| Li, J | 1 |
| Li, F | 1 |
| Li, R | 1 |
| Liu, Z | 1 |
| Huang, D | 1 |
| Martinez-Ciarpaglini, C | 1 |
| Machado, I | 1 |
| Yoshida, A | 1 |
| Nieto, G | 1 |
| Berbegall, AP | 1 |
| Blanquer-Maceíras, MT | 1 |
| Noguera, R | 1 |
| Ferrández, A | 1 |
| Navarro, S | 1 |
| Yeo, KK | 1 |
| HaDuong, JH | 1 |
| Zage, PE | 1 |
| Kletzel, M | 1 |
| Murray, K | 1 |
| Marcus, R | 1 |
| Castleberry, R | 2 |
| Zhang, Y | 2 |
| London, WB | 2 |
| Kretschmar, C | 1 |
| Mullah-Ali, A | 1 |
| Ramsay, JA | 1 |
| Bourgeois, JM | 1 |
| Hodson, I | 1 |
| Macdonald, P | 1 |
| Midia, M | 1 |
| Portwine, C | 1 |
| Gutweiler, JR | 1 |
| Yu, DC | 1 |
| Kim, HB | 1 |
| Kozakewich, HP | 1 |
| Marcus, KJ | 1 |
| Shamberger, RC | 1 |
| Weldon, CB | 1 |
| Turano, S | 1 |
| Mastroianni, C | 1 |
| Manfredi, C | 1 |
| Biamonte, R | 1 |
| Ceniti, S | 1 |
| Liguori, V | 1 |
| De Simone, R | 1 |
| Conforti, S | 1 |
| Filice, A | 1 |
| Rovito, A | 1 |
| Viscomi, C | 1 |
| Patitucci, G | 1 |
| Palazzo, S | 1 |
| De Ioris, MA | 1 |
| Castellano, A | 2 |
| Ilari, I | 2 |
| Garganese, MC | 1 |
| Natali, G | 1 |
| Inserra, A | 2 |
| De Vito, R | 1 |
| Ravà, L | 1 |
| De Pasquale, MD | 1 |
| Locatelli, F | 1 |
| Donfrancesco, A | 2 |
| Jenkner, A | 2 |
| Osawa, S | 1 |
| Kumabe, T | 1 |
| Saito, R | 1 |
| Sonoda, Y | 1 |
| Niizuma, H | 1 |
| Watanabe, M | 1 |
| Tominaga, T | 1 |
| Miranda Soares, PB | 1 |
| Quirino Filho, S | 1 |
| Pereira DE Souza, W | 1 |
| Ferreti Bonan, PR | 1 |
| Martelli-Júnior, H | 1 |
| Chen, N | 1 |
| Hanly, L | 1 |
| Rieder, M | 1 |
| Yeger, H | 1 |
| Koren, G | 1 |
| Zhang, WL | 1 |
| Huang, DS | 1 |
| Yang, YP | 1 |
| Liu, XC | 1 |
| Wu, YP | 1 |
| Sugito, K | 1 |
| Furuya, T | 1 |
| Kaneda, H | 1 |
| Masuko, T | 1 |
| Ohashi, K | 1 |
| Inoue, M | 1 |
| Ikeda, T | 1 |
| Koshinaga, T | 1 |
| Yagasaki, H | 1 |
| Mugishima, H | 1 |
| Maebayashi, T | 1 |
| Abdel Rahman, H | 1 |
| Moussa, EA | 1 |
| Zekri, WZ | 1 |
| El Debawy, E | 1 |
| Mostafa, NE | 1 |
| Yones, A | 1 |
| Ezzat, S | 1 |
| Rayan, Ael R | 1 |
| Kushner, BH | 2 |
| Modak, S | 1 |
| Kramer, K | 1 |
| Basu, EM | 1 |
| Roberts, SS | 1 |
| Cheung, NK | 2 |
| Carli, M | 1 |
| Passone, E | 1 |
| Perilongo, G | 1 |
| Bisogno, G | 1 |
| Milano, GM | 1 |
| De Sio, L | 1 |
| Cozza, R | 1 |
| Fidani, P | 1 |
| Deb, G | 1 |
| De Laurentis, C | 1 |
| Dominici, C | 1 |
| Yamada, K | 1 |
| Sugiura, H | 1 |
| Suzuki, Y | 1 |
| Takahashi, M | 1 |
| Bagatell, R | 1 |
| Rumcheva, P | 1 |
| Cohn, SL | 1 |
| Look, AT | 1 |
| Brodeur, GM | 1 |
| Frantz, C | 1 |
| Joshi, V | 2 |
| Thorner, P | 1 |
| Rao, PV | 1 |
| Bowman, LC | 1 |
| Zhen, ZJ | 1 |
| Sun, XF | 1 |
| Xia, Y | 1 |
| Wang, ZH | 1 |
| Ling, JY | 1 |
| Cairo, MS | 1 |
| Kamen, BA | 1 |
| Frenkel, E | 1 |
| Colvin, OM | 1 |
| Castleberry, RP | 1 |
| Cantor, AB | 1 |
| Green, AA | 1 |
| Berkow, RL | 1 |
| Buchanan, GR | 1 |
| Leventhal, B | 1 |
| Mahoney, DH | 1 |
| Smith, EI | 1 |
| Hayes, FA | 1 |
| Lowis, SP | 1 |
| Pearson, AD | 2 |
| Reid, MM | 1 |
| Craft, AW | 1 |
| Matsumoto, K | 2 |
| Miyajima, Y | 2 |
| Numata, S | 1 |
| Mori, H | 1 |
| Fukuda, M | 2 |
| Horibe, K | 2 |
| Voûte, PA | 1 |
| van den Berg, H | 1 |
| Behrendt, H | 1 |
| Michiels, E | 1 |
| de Kraker, J | 4 |
| Kirch, C | 1 |
| Gachot, B | 1 |
| Germann, N | 1 |
| Blot, F | 1 |
| Nitenberg, G | 1 |
| Fernandez, MC | 1 |
| Krailo, MD | 1 |
| Gerbing, RR | 1 |
| Matthay, KK | 1 |
| Fulda, S | 1 |
| Fichtner, I | 1 |
| Hero, B | 2 |
| Berthold, F | 2 |
| Kondo, M | 1 |
| Inaba, J | 1 |
| Miyashita, Y | 1 |
| Hunneman, DH | 1 |
| Gahr, M | 1 |
| Pratt, CB | 1 |
| Watts, RG | 1 |
| Iwasaku-Fujimoto, M | 1 |
| Fujiwara, F | 1 |
| Todo, S | 1 |
| Morioka, Y | 1 |
| Imashuku, S | 1 |
| Pinkerton, CR | 1 |
| Zucker, JM | 1 |
| Hartmann, O | 2 |
| Pritchard, J | 4 |
| Broadbent, V | 1 |
| Morris-Jones, P | 1 |
| Breatnach, F | 1 |
| Craft, AE | 1 |
| Wallendszus, KR | 1 |
| Gieron, MA | 1 |
| Barak, LS | 1 |
| Estrada, J | 1 |
| Ninane, J | 1 |
| Kellie, SJ | 2 |
| Lilleyman, JS | 2 |
| Bowman, A | 2 |
| Muchi, H | 1 |
| Taniguchi, Y | 1 |
| Makino, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PHASE III MULTICENTRE TRIAL OF TREATMENT OF NEUROBLASTOMA IN CHILDREN AND ADOLESCENTS[NCT00002802] | Phase 3 | 500 participants (Anticipated) | Interventional | 1990-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for ifosfamide and Neuroblastoma
| Article | Year |
|---|---|
Paraspinal synovial sarcoma as an unusual postradiation complication in pediatric abdominal neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 18; Chromosomes, Human, X; | 2008 |
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carboplati | 2013 |
Ifosfamide in pediatric solid tumors.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Germinoma; Humans; Ifosf | 2003 |
The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Ifosfamide; L | 1995 |
Current studies of ifosfamide for pediatric solid tumors and leukemia in the United States.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Chil | 1992 |
9 trials available for ifosfamide and Neuroblastoma
| Article | Year |
|---|---|
Did salvage ICE chemotherapy improve the outcome in primary resistant/relapsing stage III/IV neuroblastoma?
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Pres | 2011 |
Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2004 |
Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
Topics: Abdominal Neoplasms; Adolescent; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Proto | 2005 |
Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 1994 |
Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Child, Preschool; C | 1993 |
A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati | 2000 |
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Topics: Adolescent; Amifostine; Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Cell Divi | 2001 |
Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma.
Topics: 3-Iodobenzylguanidine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marro | 2001 |
Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group.
Topics: Bone Marrow Diseases; Child; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; Male; Neuroblas | 1987 |
27 other studies available for ifosfamide and Neuroblastoma
| Article | Year |
|---|---|
A report on second neo-plasms in seven children with solid tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisp | 2022 |
Extra-Adrenal Adult Neuroblastoma With Aberrant Germ Cell Marker Expression: Maturation After Chemotherapy as an Important Clue to a Challenging Diagnosis.
Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemo | 2019 |
The Use of Continuous Veno-Venous Hemodiafiltration in the Management of Ifosfamide-induced Encephalopathy: A Case Report.
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Child; Female; Hemodiafiltration; Humans; Ifosfam | 2016 |
Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 2008 |
Hepatoblastoma presenting with focal nodular hyperplasia after treatment of neuroblastoma.
Topics: Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine.
Topics: Adult; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Doxorubicin; Endocrine Gland Neo | 2010 |
Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; | 2011 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin | 2011 |
Neuroblastoma in an adult: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Brain Neoplasms; Carboplatin | 2010 |
The effect of N-acetylcysteine on the antitumor activity of ifosfamide.
Topics: Acetylcysteine; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Drug Interaction | 2011 |
[Mobilization and collection of autologous peripheral blood stem cells by CIE or IEV protocol in children with malignant solid tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Epirubicin; Etoposide; Fema | 2011 |
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carbop | 2011 |
[A case of retroperitoneal neuroblastoma in an adult with extensive bone marrow metastasis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carboplatin; Dactinomy | 2004 |
[Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carbo | 2006 |
Ifosfamide: should the honeymoon be over?
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Child; Cisplatin; Cyclophosp | 1995 |
[Combination chemotherapy of ifosfamide and etoposide for advanced neuroblastoma].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dr | 1995 |
Ifosfamide in the treatment of pediatric malignancies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 1996 |
Recurrent ifosfamide-induced hyponatraemia.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Cranial Nerve Neoplasms; Female; Humans; Hyponatremia | 1997 |
Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Mar | 2001 |
Combination chemotherapy with ifosfamide and etoposide is effective in the treatment of central nervous system metastasis of childhood neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Etoposide; Female; | 1992 |
Cyclophosphamide versus ifosfamide in paediatric oncology.
Topics: Adolescent; Child; Cyclophosphamide; Drug Administration Schedule; Humans; Ifosfamide; Neuroblastoma | 1990 |
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
Topics: Bone Neoplasms; Child; Cyclophosphamide; Cystitis; Female; Hematuria; Humans; Ifosfamide; Leukemia; | 1990 |
Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen). The European Neuroblastoma Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Dose-Response Relations | 1990 |
Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors.
Topics: Brain Neoplasms; Child, Preschool; Coma; Electroencephalography; Female; Humans; Ifosfamide; Kidney | 1988 |
Ifosfamide in previously untreated disseminated neuroblastoma. Results of Study 3A of the European Neuroblastoma Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Cyclophosphamide; Femal | 1988 |
[Ifosfamide treatment for children with malignant tumor].
Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Female; Humans; Ifosfamide; Male; Mice; Mice, N | 1987 |
Ifosfamide neurotoxicity in children.
Topics: Adolescent; Adult; Central Nervous System Diseases; Child; Drug Evaluation; Female; Humans; Ifosfami | 1987 |